Valeant Pharma (VRX) Shares See Early Bounce Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Asia stocks rise, yen plumbs 34-year low as BOJ stands pat on rates
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Valeant Pharma (VRX) Receives Subpoena from California Department of Insurance
November 9, 2016 4:44 PM ESTValeant Pharma (NYSE: VRX) disclosed the following in its Form 10-Q on Wednesday:
Investigation by the California Department of Insurance
On or about September 16, 2016,... More
Valeant Pharma (VRX): Yet Another Guidance Cut - Jefferies
November 9, 2016 7:40 AM ESTJefferies analyst, David Steinberg, reiterated his Buy rating on shares of Valeant Pharmaceuticals (NYSE: VRX) but cut his price target nearly in half to $22 from $40. While Q3 revs of $2.444B were just slightly (0.7%) below his est, EPS came in well below consensus ($1.55 vs $1.75) due... More
